Results 51 to 60 of about 73,286 (248)

Effect of Continuous Care Model on Recurrence of Vulvovaginal Candidiasis Infection among Pregnant Women [PDF]

Egyptian Journal of Health Care
Background: Recurrent Vulvovaginal candidiasis infection is a global health problem for pregnant women associated with negative impacts on sexual and family lives that requires specific control practices.
Doaa Shehta Said, Walaa Khalaf Gooda, Ebtesam Ali Mohamed, Hanan Elzeblawy Hassan   +3 more
doaj   +1 more source

β-Glucan induces reactive oxygen species production in human neutrophils to improve the killing of Candida albicans and Candida glabrata isolates from vulvovaginal candidiasis. [PDF]

PLoS ONE, 2014
Vulvovaginal candidiasis (VVC) is among the most prevalent vaginal diseases. Candida albicans is still the most prevalent species associated with this pathology, however, the prevalence of other Candida species, such as C. glabrata, is increasing.
Patricia de Souza Bonfim-Mendonça, Bianca Altrão Ratti, Janine da Silva Ribeiro Godoy, Melyssa Negri, Nayara Cristina Alves de Lima, Adriana Fiorini, Elaine Hatanaka, Marcia Edilaine Lopes Consolaro, Sueli de Oliveira Silva, Terezinha Inez Estivalet Svidzinski   +9 more
doaj   +1 more source

Protective efficacy of the pan-fungal vaccine NXT-2 against vulvovaginal candidiasis in a murine model

npj Vaccines
Vulvovaginal candidiasis (VVC) is the most common clinical manifestation of candidiasis, affecting 75% of women. Despite high incidence rates, increasing drug resistance, and potential teratogenic effects of current treatments, there are no approved ...
Daniel A. Wychrij, Taylor I. Chapman, Emily Rayens, W. Rabacal, H. Willems, Kwadwo O Oworae, Brian M. Peters, K. A. Norris   +7 more
semanticscholar   +1 more source

Interplay of the microbiome and antifungal therapy in recurrent vulvovaginal candidiasis (RVVC): A narrative review.

Journal of Medical Microbiology, 2023
Recurrent vulvovaginal candidiasis (RVVC) is a microbial, immune and sexual health disorder impacting up to 10 % of the adult female population. Fluconazole is a well-established antifungal drug commonly utilized for acute and long-term RVVC treatment ...
Moira Bradfield Strydom, Sohil Khan, Ramesh L Walpola, R. Ware, E. Tiralongo   +4 more
semanticscholar   +1 more source

Investigation of the relationship between different Candida species and some risk factors affecting the incidence of Vulvovaginal Candidiasis [PDF]

Majallah-i Zanān, Māmā̓ī va Nāzā̓ī-i Īrān, 2019
Introduction: Vulvovaginal candidiasis (VVC) is a yeast infection and is one of the most common causes of women's referral to the physician. The aim of this study was to investigate the relationship between different Candida species and some risk factors
Seyedeh Sedigheh Hosseini, Ezzatallah Ghaemi, Farhad Niknejad, Hamidreza Joshaghani, Mina Rabiee, Fahimeh Azadi, Toktam Sharafi, Naemeh Javid, Mahboobeh Kabir, Saba Modi, Farideh Jafari, Zahra Kamizi   +11 more
doaj   +1 more source

Miconazole-loaded nanoparticles coated with hyaluronic acid to treat vulvovaginal candidiasis.

European Journal of Pharmaceutical Sciences, 2023
Miconazole-loaded nanoparticles coated with hyaluronic acid (miconazole-loaded nanoparticles/HA) were developed to overcome the limitations of the conventional therapy of the vulvovaginal candidiasis (VVC).
Aniely dos Reis Teixeira, Amanda de Vasconcelos Quaresma, Renata Tupinambá Branquinho, Stephanie Lourrani Evangelista Neves Santos, J. T. de Magalhães, Fábio Rodrigues da Silva, M. B. de Freitas Marques, S. A. L. de Moura, A. P. M. Barboza, Marcelo Gonzaga de Freitas Araújo, G. R. da Silva   +10 more
semanticscholar   +1 more source

Prevalence of vulvovaginal candidiasis in females in the reproductive age group [PDF]

, 2019
Background: Vulvovaginal candidiasis (VVC) is a common infection among reproductive age group females. The objective of present study is to determine the prevalence of vulvovaginal candidiasis, its distribution and association of risk factors among ...
Salvi, Meena, Vargas Torres, Ludy Alexandra, Rodríguez Sáenz, Ana Yervid   +2 more
core   +1 more source

Vaginal lipidomics of women with vulvovaginal candidiasis and cytolytic vaginosis: A non-targeted LC-MS pilot study. [PDF]

PLoS ONE, 2018
OBJECTIVE:To characterize the lipid profile in vaginal discharge of women with vulvovaginal candidiasis, cytolytic vaginosis, or no vaginal infection or dysbiosis. DESIGN:Cross-sectional study.
José Marcos Sanches, Paulo César Giraldo, Rose Amaral, Marcos Nogueira Eberlin, Lygia Azevedo Marques, Isabel Migliorini, Marcel Nakahira, Michel Jan Marinus Bieleveld, Michelle Garcia Discacciati   +8 more
doaj   +1 more source

Virulence Factors of Candida spp. and Host Immune Response Important in the Pathogenesis of Vulvovaginal Candidiasis

International Journal of Molecular Sciences, 2022
Vulvovaginal candidiasis (VVC) is one of the most common types of vaginal infections in women around the world and is often underestimated by both patients and doctors.
Paulina Czechowicz, J. Nowicka, G. Gościniak   +2 more
semanticscholar   +1 more source

A Phase 3, multicenter, randomized, placebo-controlled trial of monthly oral ibrexafungerp to reduce the incidence of recurrent vulvovaginal candidiasis.

American Journal of Obstetrics and Gynecology
BACKGROUND Recurrent vulvovaginal candidiasis develops in 5-9% of people assigned female at birth and has a serious impact on quality of life. Oral ibrexafungerp is a first-in-class, non-azole, triterpenoid antifungal approved in the United States for ...
O. Goje, N. Azie, D. Angulo, Ryan H. Sobel, P. Nyirjesy, Jack D. Sobel   +5 more
semanticscholar   +1 more source